UNSPSC 51431604: Fendiline

This classification denotes a calcium channel blocker with the molecular formula C23H25N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S253D559A8, chemically known as benzenepropanamine, gamma-phenyl-n-(1-phenylethyl)- but generally known as fendiline, which bears US NIH Compound Identifier 3336. European Medicines Agency schedules Fendiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07554MIG. The term FENDILINE is an International Non-Proprietary Name.

UNSPSC 51431604 Fendiline, a Commodity code, covers emergency medications and pharmaceuticals for state and local government healthcare operations, particularly emergency medical services. Recent state and local solicitations under this code reflect procurement of advanced life support medications supplied directly to fire rescue and EMS operations, as well as broader pharmaceutical procurement frameworks for health agencies and cooperative purchasing alliances. The City of Tampa's Purchasing Department and the Texas Health and Human Services Commission represent the mix of issuing bodies — municipal fire services and state health programs — that buy under this classification, alongside multi-state cooperative purchasing alliances serving participating state and local government facilities.

The most recent activity concentrates in Florida and Minnesota, with Texas conducting early market intelligence on direct-to-manufacturer pharmacy programs. The City of Tampa's April 2026 sealed bid for Advanced Life Support Medications (Bid No. 26-P-00188) solicited 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials for Tampa Fire Rescue, with an estimated contract value of $40,000.00, delivery required within ten calendar days, and award to the lowest responsive bidder by June 7, 2026; the solicitation offered a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 closing March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, requiring vendor products to be available by May 15, 2026, with resulting agreements effective July 1, 2026. Texas Health and Human Services Commission posted an RFI in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs without disclosed award value or formal competitive timeline.